OR WAIT null SECS
October 14, 2024
Article
Patients with IBD or arthritis were not found to be at a significantly higher risk of serious infection with a biosimilar versus originator of the common drugs.
The ustekinumab biosimilar will be available in early 2025, with indications to treat psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
October 09, 2024
BSC and Fresnius Kabi reached a deal facilitated by Evio Pharmacy Solutions by sidestepping pharmacy benefit managers.
October 08, 2024
The biosimilars month in review highlights a new approval and 2023 cost savings
October 01, 2024
The approval marks the fourth biosimilar approved for ustekinumab, for all approved indications.
September 28, 2024
To date, biosimilars have supported 495 million incremental days of therapy that patients would otherwise not have received.
September 12, 2024
MYL-1701P showed equivalent efficacy, with comparable safety and immunogenicity, to reference aflibercept in the Phase 3 INSIGHT trial.
September 06, 2024
Participants in a study in China also experienced comparable safety and immunogenicity.
September 05, 2024
The biosimilars month in review highlights recent data demonstrating clinical equivalence and efforts to improve their access.
September 03, 2024
Patients receiving Humira or Hulio had the highest satisfaction levels across different measures.
